Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 6/20 | 0.79 |
| ▸ | MAPT | P10636 | 5/20 | 0.49 |
| ▸ | PTGES | O14684 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | HGFAC | Q04756 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | F2 | P00734 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4625346 | 0.91 | ALOX5 (0.64) | ALOX5MAPTPTGESALDH1A1MEN1 | |
| SCHEMBL4626127 | 0.89 | ALOX5 (0.61) | ALOX5MAPTPTGESALDH1A1HGFAC | |
| SCHEMBL4626136 | 0.89 | ALOX5 (0.61) | ALOX5MAPTPTGESALDH1A1MEN1 | |
| SCHEMBL13400268 | 0.89 | ALOX5 (1.00) | ALOX5MAPTPTGESALDH1A1MEN1 | |
| SCHEMBL4625128 | 0.86 | ALOX5 (0.76) | ALOX5MAPTPTGESALDH1A1MEN1 | |
| SCHEMBL4625149 | 0.85 | ALOX5 (0.64) | ALOX5MAPTPTGESALDH1A1KMT2A | |
| SCHEMBL14586194 | 0.83 | ALOX5 (0.57) | ALOX5MAPTPTGESALDH1A1KMT2A | |
| SCHEMBL8300126 | 0.83 | ALOX5 (0.54) | ALOX5MAPTPTGESALDH1A1MEN1 | |
| SCHEMBL4625145 | 0.82 | ALOX5 (0.61) | ALOX5MAPTPTGESALDH1A1KMT2A | |
| SCHEMBL4625225 | 0.82 | ALOX5 (0.58) | ALOX5MAPTPTGESALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1682076-A4 | INHIBITORS OF CORONAVIRUS PROTEASE AND METHODS OF USE THEREOF | FULCRUM PHARMACEUTICALS INC (US) | 2008-02-06 | — | — | EP | disclosed |
| US-7183267-B2 | β-lactamase inhibitors and methods of use thereof | THE JOHNS HOPKINS UNIVERSITY (US) | 2007-02-27 | — | — | US | disclosed |
| US-7183267-B2 | β-lactamase inhibitors and methods of use thereof | THE JOHNS HOPKINS UNIVERSITY (US) | 2007-02-27 | — | — | US | disclosed |
| US-7183267-B2 | β-lactamase inhibitors and methods of use thereof | THE JOHNS HOPKINS UNIVERSITY (US) | 2007-02-27 | — | — | US | disclosed |
| EP-1682076-A2 | INHIBITORS OF CORONAVIRUS PROTEASE AND METHODS OF USE THEREOF | Fulcrum Pharmaceuticals, Inc. (US) | 2006-07-26 | — | — | EP | disclosed |
| EP-1635812-A2 | BETA-LACTAMASE INHIBITORS AND METHODS OF USE THEREOF | Fulcrum Pharmaceuticals, Inc. (US) | 2006-03-22 | — | — | EP | disclosed |
| US-20050267071-A1 | Inhibitors of coronavirus protease and methods of use thereof | FULCRUM PHARMACEUTICALS, INC. (US) | 2005-12-01 | — | — | US | disclosed |
| US-20050124580-A1 | Beta-lactamase inhibitors and methods of use thereof | FULCRUM PHARMACEUTICALS, INC. (US) | 2005-06-09 | — | — | US | disclosed |
| WO-2005041904-A2 | INHIBITORS OF CORONAVIRUS PROTEASE AND METHODS OF USE THEREOF | FULCRUM PHARMACEUTICALS, INC. (US) | 2005-05-12 | — | — | WO | disclosed |
| WO-2005041904-A2 | INHIBITORS OF CORONAVIRUS PROTEASE AND METHODS OF USE THEREOF | FULCRUM PHARMACEUTICALS, INC. (US) | 2005-05-12 | — | — | WO | disclosed |
| WO-2005004799-A2 | β-LACTAMASE INHIBITORS AND METHODS OF USE THEREOF | FULCRUM PHARMACEUTICALS, INC. (US) | 2005-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050267071-A1 | Inhibitors of coronavirus protease and methods of use thereof | ACE, ACE2, CTRL | ALOX5 1853/4885MAPT 1569/4885PTGES 3012/4885 |
| US-20050124580-A1 | Beta-lactamase inhibitors and methods of use thereof | LCT, BCHE, GAA | ALOX5 615/4885MAPT 2925/4885PTGES 2160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.